Khairul Najmi Muhammad Nawawi
Overview
Explore the profile of Khairul Najmi Muhammad Nawawi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al-Baiaty F, Ishak S, Mohd Zaki F, Masra F, Abdul Aziz D, Wan Md Zin W, et al.
BMC Pediatr
. 2024 Aug;
24(1):529.
PMID: 39160468
Background: Childhood obesity is a growing concern, and non-alcoholic fatty liver disease (NAFLD) is a significant consequence. Currently, there are no approved drugs to treat NAFLD in children. However, a...
2.
Razali N, Ali R, Muhammad Nawawi K, Yahaya A, Mohd Rathi N, Mokhtar N
World J Gastroenterol
. 2023 Nov;
29(40):5543-5556.
PMID: 37970476
Background: Phosphatidylinositol-3-kinases (PI3K) is a well-known route in inflammation-related cancer. Recent discovery on PI3K-related genes revealed a potential variant that links ulcerative colitis (UC) and colorectal cancer (CRC) with colitis-associated...
3.
Chew D, Khoo X, Lee T, Chin K, Ali R, Muhammad Nawawi K, et al.
Inflamm Bowel Dis
. 2023 Nov;
30(9):1566-1578.
PMID: 37935628
The incidence of inflammatory bowel disease (IBD) has been increasing in Southeast Asia (SEA) in tandem with its economic growth and urbanization over the past 2 decades. Specific characteristics of...
4.
Sayuti N, Muhammad Nawawi K, Goon J, Mokhtar N, Makpol S, Tan J
Antioxidants (Basel)
. 2023 Aug;
12(8).
PMID: 37627546
Non-alcoholic fatty liver disease (NAFLD) is a significant public health issue owing to its high incidence and consequences, and its global prevalence is presently 30% and rising, necessitating immediate action....
5.
Ismail N, Muhammad Nawawi K, Hsin D, Hao K, Nik Mahmood N, Chearn G, et al.
Helicobacter
. 2023 Aug;
28(6):e13017.
PMID: 37614081
Background: Despite multiple therapy regimens, the decline in the Helicobacter pylori eradication rate poses a significant challenge to the medical community. Adding Lactobacillus reuteri probiotic as an adjunct treatment has...
6.
Sayuti N, Muhammad Nawawi K, Goon J, Mokhtar N, Makpol S, Tan J
Nutrients
. 2023 Apr;
15(8).
PMID: 37111187
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease. Fucoxanthin, a red-orange marine carotenoid, is found in natural marine seaweeds with high antioxidant activity and...
7.
Lim K, Ali R, Wong Z, Mohd Zaki F, Maktar J, Muhammad Nawawi K
Saudi J Gastroenterol
. 2023 Mar;
29(5):300-308.
PMID: 36876618
Background: The use of intestinal ultrasound (IUS) in the management of inflammatory bowel disease (IBD) is emerging. We aim to determine the performance of IUS in the assessment of disease...
8.
Shafiee N, Razalli N, Shahril M, Muhammad Nawawi K, Mokhtar N, Abd Rashid A, et al.
Nutrients
. 2023 Feb;
15(4).
PMID: 36839339
Obesity-mediated inflammation represents a key connection between the intake of foods with high inflammatory potential and colorectal cancer (CRC) risk. We aimed to explore the association between energy-adjusted dietary inflammatory...
9.
Ayob N, Muhammad Nawawi K, Mohamad Nor M, Ali R, Ahmad H, Oon S, et al.
Biomedicines
. 2023 Feb;
11(2).
PMID: 36831176
The prevalence of non-alcoholic fatty liver disease (NAFLD) has soared globally. As our understanding of the disease grows, the role of the gut-liver axis (GLA) in NAFLD pathophysiology becomes more...
10.
Razali N, Ali R, Muhammad Nawawi K, Yahaya A, Mokhtar N
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232773
Chronic relapsing inflammatory bowel disease is strongly linked to an increased risk of colitis-associated cancer (CAC). One of the well-known inflammatory carcinogenesis pathways, phosphatidylinositol 3-kinase (PI3K), was identified to be...